ArticleDiabetologia2022
IgM-associated gut bacteria in obesity and type 2 diabetes in C57BL/6 mice and humans.
Article in Diabetologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Gut microbiota in early and established stages of rheumatoid arthritis: from pathogenesis to promising prevention and treatment.Annals of medicine · 2026Review
- Human Islet miR-199a-5p and miR-214-3p Associate With Donor Age, BMI, and Sex and Mediate Cellular Aging in Islet-Derived Cells.Acta physiologica (Oxford, England) · 2026Article
- Subcutaneous white adipose tissue-derived extracellular vesicles maintain intestinal homeostasis via IgA biosynthesis in aging mice.The Journal of clinical investigation · 2025Article
- Intestinal antibody repertoire is altered by diabetes and varies depending on the pathogenesis.Biochemistry and biophysics reports · 2025Article
- MiCML: a causal machine learning cloud platform for the analysis of treatment effects using microbiome profiles.BioData mining · 2025Article
- Mechanisms of gut microbiota in host fat deposition: metabolites, signaling pathways, and translational applications.Frontiers in microbiology · 2025Review
- Microbiota and enteric nervous system crosstalk in diabetic gastroenteropathy: bridging mechanistic insights to microbiome-based therapies.Frontiers in cellular and infection microbiology · 2025Review
- Tlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosis.Nature communications · 2024Article
- Article
- Intestinal IgA-Coated Bacteria in Healthy- and Altered-Microbiomes (Dysbiosis) and Predictive Value in Successful Fecal Microbiota Transplantation.Microorganisms · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
aims/hypothesisIgM is the primary antibody produced by B cells and we hypothesise that IgM antibodies to gut microbiota may play a role in immunometabolism in obesity and type 2 diabetes. To test our hypothesis, we used B6 mice deficient in activation-induced cytidine deaminase (Aid
methodsWe studied the immunometabolic effects and gut microbial changes in high-fat-diet-induced obesity (HFDIO) in Aid
resultsCompared with wild-type mice, Aid CONCLUSIONS/
interpretationOur results suggest that IgM-bound gut microbiota may play an important role in the immuno-pathogenesis of obesity and type 2 diabetes, and provide a novel link between IgM in obesity and type 2 diabetes in both mice and humans. DATA AVAILABILITY: The 16s rRNA sequencing datasets supporting the current study have been deposited in the NCBI SRA public repository ( https://www.ncbi.nlm.nih.gov/sra ; accession no. SAMN18796639).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.